Entod Pharma Onboards Prof Vivek Padgaonkar as an Independent Director

He holds directorships at Martin & Harris Labs Ltd, Bervin Investment & Leasing Limited, and Juvenor Healthcare.

Entod Pharmaceuticals has appointed Prof Vivek Padgaonkar as a non-executive independent director.

Prof Padgaonkar brings experience from his work with lobbying and think-tank organizations on healthcare issues and collaborations with government ministries that shaped pharmaceutical policies.

Dr Vivek Padgaonkar, Independent Director, Entod Pharmaceuticals, said, “I am honored to join ENTOD Pharmaceuticals and contribute to its innovation driving mission.”

He holds directorships at Martin & Harris Labs, Bervin Investment & Leasing Limited, and Juvenor Healthcare.

Entod Pharmaceuticals, specializing in ophthalmology, ENT, and dermatological medicine, operates in over 67 countries.

Earlier this year, the company inaugurated its research and development center, equipped with molecular and formulation research tools, microbiology testing facilities, and quality assurance/quality control analytical equipment.

Nikkhil K Masurkar, CEO, Entod Pharmaceuticals, said, “We are thrilled to welcome Prof Padgaonkar. His experience will be invaluable as we strive to position Entod and the Indian pharmaceutical sector as global leaders in innovation.”

Recent Appointments in the Healthcare Space

Morgan Stanley-backed ClearMedi Healthcare recently appointed Lokesh Dhamaniya as the group's chief financial officer (CFO). Dhamaniya has a notable track record and over 12 years of extensive experience in economic strategy and leadership.

With this appointment, ClearMedi Healthcare, a rapidly expanding Morgan Stanley Invested Company, expects to grow at an exponential rate with Dhamaniya's expertise in financial strategy and leadership.

In July, Paras Health appointed Usha Rajeev as an Independent Director. Rajeev brings experience from her previous role at Price Waterhouse, India, a member firm of Price Waterhouse Coopers (PwC) International, where she served as a Partner for over 19 years until her retirement in 2018.

Her extensive governance, audit, and risk management background is expected to enhance the board's oversight capabilities and support Paras Health's strategic objectives.

Gland Pharma named Srinivas Sadu, the incumbent MD and CEO, as the executive chairman and CEO of the company, effective June 10, 2024.